OncoMatch/Clinical Trials/NCT06711185
Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy
Is NCT06711185 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Dapagliflozin 10 mg for breast cancer.
Treatment: Dapagliflozin 10 mg — Prospective, randomized, double-blind, controlled clinical trial to compare the effect of 9 months of treatment with dapagliflozin vs. placebo on anthracycline-induced cardiotoxicity in patients with breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Lab requirements
Kidney function
glomerular filtration rate >= 30 ml/min/1.73 m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify